Abstract We are delighted to invite you to an upcoming seminar on animal models for blood-brain barrier (BBB) crossing. The BBB is a formidable barrier that restricts the entry of many therapeutic agents into the brain, posing a significant challenge in the treatment of neurological disorders. However, recent breakthroughs in utilizing receptor-mediated transcytosis have opened new avenues for effective drug delivery. Biocytogen has developed a series of mice models of aiding large molecular drugs penetrating into BBB, and these models play a crucial role in evaluating the efficiency of various shuttle. Our seminar will delve into the latest advancements in these animal models, showcasing how they can be utilized to optimize drug delivery strategies and gain valuable insights into the future of neuroscience research. Key case studies will include: The TFR1 humanized mouse model facilitates the delivery of various large-molecule drugs across the BBB and muscle tissue. CD98HC is a rising star in large-molecular drugs penetrating BBB. IGF1R: a promising target across oncology, autoimmunity, ophthalmology, and neuroscience. Biocytogen is a comprehensive repository of animal models, offering a diverse array of models across multiple disease areas, including neurology, metabolism, oncology, and autoimmune diseases. This extensive collection serves as a robust platform for elucidating disease mechanisms, conducting preclinical studies, and advancing clinical research. Speaker Meiqi Zhang, Ph.D Product Manager BioMice Product Department Biocytogen (Beijing) Pharmaceutical Co. Ltd. Dr. Meiqi Zhang received her PhD in Peking University majoring in the mechanism of copper chaperone proteins and the application of copper chaperone antagonists in tumor metal immunology. She subsequently joined Biocytogen as a Product Manager in the BioMice Product Department. Dr. Zhang manages the development of humanized mouse models for neurological disorders and mice models aiding large model.
